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The human parvovirus adeno-associated virus type 2 (AAV-2) possesses many features that make it
an attractive vector for gene delivery in vivo. However, its broad host range may limit its usefulness
and effectivity in several gene therapy applications in which transgene expression needs to be
limited to a specific organ or cell type. In this study, we explored the possibility of directing
recombinant AAV-2 transduction by incorporating targeting peptides previously isolated by in vivo
phage display. Two putative loops within the AAV-2 capsid were examined as sites for incorpora-
tion of peptides. We tested the effects of deleting these loops and different strategies for the
incorporation of several targeting peptides. The tumor-targeting sequence NGRAHA and a Myc
epitope control were incorporated either as insertions or as replacements of the original capsid
sequence. Viruses were assessed for packaging, accessibility of incorporated peptides, heparin
binding, and transduction in a range of cell lines. Whereas recombinant viruses containing mutant
capsid proteins were produced efficiently, transduction of several cell lines was significantly
impaired for most modifications. However, certain mutants containing the peptide motif NGR,
which binds CD13 (a receptor expressed in angiogenic vasculature and in many tumor cell lines),
displayed an altered tropism toward cells expressing this receptor. Based on this work and previous
studies, possible strategies for achieving in vivo targeting of recombinant AAV-2 are discussed.INTRODUCTION
Adeno-associated virus type 2 (AAV-2) is a human parvo-
virus being developed into a promising delivery system
for gene therapy applications. Recombinant adeno-asso-
ciated virus (rAAV) vectors possess a number of attractive
features, including lack of pathogenicity, ability to trans-
duce both dividing and nondividing cells, and long-term
transgene expression in vitro and in vivo (reviewed in 1, 2).
rAAV vectors have been used to achieve expression of a
large number of genes in a variety of cells and organs,
including muscle, liver, brain, and lung (3–6). The wide
host range of AAV may prove to be disadvantageous for
systemic gene therapy, since it will result in transduction
and possibly integration of the recombinant genome in
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weitzman@salk.edu.964unwanted cells and tissues. The ability to redirect rAAV
infectivity and host range will circumvent these problems
and may also enable the administration of lower doses of
vector. Certain tissues and cell types are naturally resis-
tant to rAAV transduction. These include human leuke-
mia cell lines, airway epithelia, and CD341 cells (7–11).
This may be due to the absence of receptors for AAV or
other intracellular factors involved in infection. Heparan
sulfate proteoglycan has been reported to be the primary
attachment receptor for AAV-2 (12). In addition, human
fibroblast growth factor receptor 1 (FGFR-1) and aVb5
integrin have been proposed to act as secondary receptors
(13, 14). Following receptor binding, AAV-2 particles en-
ter the cell via receptor-mediated endocytosis through
clathrin-coated pits, and dynamin is also involved in
AAV-2 trafficking through the cytoplasm via microfila-
ments and microtubules (15–17). Most of the virus parti-
cles accumulate in a perinuclear pattern, with a slow entry
of intact virions into the nucleus (17–19).
AAV particles have a diameter of 20–25 nm and contain
a single-stranded genome of approximately 4700 nucleo-
tides (20–22). The genome contains two open readingMOLECULAR THERAPY Vol. 3, No. 6, June 2001
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dicted to be within surface loops (33). A 14-amino-acid
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Cframes, designated rep and cap, flanked by inverted termi-
nal repeats which contain all the cis requirements for
replication and packaging (23). Using alternate splicing
and different translational initiation codons the virus
generates three structural proteins, VP1, VP2, and VP3,
from the cap gene (24). The small icosahedral capsid is
composed of 60 subunits with a relative stoichiometry of
1:1:10 for VP1, VP2, and VP3. Although the three-dimen-
sional structure of the AAV capsid has not yet been deter-
mined, those of some related parvoviruses have been
solved by X-ray crystallography. The atomic structures are
known for canine parvovirus (CPV) (25), feline panleuko-
penia virus (26), minute virus of mice (27), and the hu-
man parvovirus B19 (28). Parvoviral capsids contain a
core structure comprising an eight-stranded b-barrel mo-
tif, similar to other icosahedral viruses. Between several
strands of the b-barrel are large insertions that make up
the majority of the capsid’s surfaces. The surface features
of the CPV capsid include a hollow cylinder at the fivefold
axis of symmetry which is surrounded by a circular de-
pression (canyon), a prominent protrusion at the three-
fold axis of symmetry (threefold spike), and a depression
(dimple), spanning the twofold axis of symmetry. Align-
ments of parvoviral capsids reveal a high sequence con-
servation in the strands which make up the b-barrel motif
(29). In contrast, sequence homologies in regions that
code for the surface of the capsid are lower, consistent
with an involvement in determining the different viral
host ranges. Despite a divergence in sequence, antigenic
sites are often located in analogous regions. Recently,
several antigenic regions of AAV-2 have been mapped (30,
31) and their involvement in AAV-2-cell interaction and
neutralization of AAV-2 infection was studied. Based on
sequence alignments, most antigenic peptides in AAV
correspond to similarly exposed regions in the different
parvoviruses and they putatively map to the cylinder, the
threefold spike loop, and the region between the twofold
depression and the threefold spike (30, 31).
Strategies currently being explored for targeting viral
vectors include bispecific conjugates and genetically mod-
ified capsids. Both of these approaches have recently been
adapted for rAAV vectors (reviewed in 31a). In one study
bispecific antibodies recognizing the AAV-2 viral capsid
and a specific cell surface receptor were employed to re-
target AAV-2 to human megakaryocytes that were non-
permissive for normal AAV infection (9). The use of bispe-
cific conjugates is not always amenable to scale-up for
clinical production and they also suffer from instability in
vivo. Therefore a more attractive approach to vector retar-
geting is the genetic incorporation of targeting peptides
into the rAAV capsid. The first attempt at expanding the
tropism of AAV fused the single-chain variable fragment
of a monoclonal antibody against human CD34 protein
onto the N-terminus of the VP2 capsid protein and dem-
onstrated improved infectivity of hematopoietic progen-
itor cells (32). Several recent reports have begun to address
structural features of AAV capsids in order to identify sites
amenable to incorporation of peptides. One study sug-
gested six possible sites in the AAV capsid that were pre-MOLECULAR THERAPY Vol. 3, No. 6, June 2001
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inserted into these sites and virus was produced. In three
mutants the peptide was exposed on the capsid surface
and one of these showed preferential transduction of in-
tegrin-expressing cells. Rabinowitz et al. employed linker
insertional mutagenesis to place small peptide sequences
(three to five amino acids) randomly across the entire
capsid coding region (34). Mutants fell into three pheno-
typic groups, depending on their ability to assemble cap-
sids, package DNA, and transduce cells. Recently, Wu et al.
reported a broad mutational analysis of the AAV-2 capsid
that identified several sites amenable to the incorporation
of peptides (35). They also identified regions involved in
heparin binding and were able to demonstrate altered
tropism of viruses engineered to contain the serpin recep-
tor ligand. It has been shown that the accessibility of
incorporated peptides can also be affected by the compo-
sition of flanking residues (J. Bartlett, personal communi-
cation).
A combination of two important parameters will deter-
mine the success of genetically modified capsids for retar-
geting viral vectors in vivo. The first decision is to choose
the location for insertions. The site must be such that (i)
assembly and packaging of the virus capsid are not af-
fected and (ii) peptides must be exposed on the surface of
the virus. The second parameter is the choice of targeting
peptide. In order for a rAAV vector to be directed to a
specific tissue following intravenous administration it
will require (i) that its natural tropism be diminished and
(ii) that it contains a ligand that will recognize a receptor
accessible through the circulation and selectively ex-
pressed in the organ or tissue of interest. The versatility of
phage display technology has made it possible to screen
for targeting peptides in vivo. The screening process in-
volves injecting a phage library into an experimental an-
imal and rescuing phage from the desired target by infect-
ing host bacteria with tissue extract. Repeated selection
yields phage that home preferentially to the target tissue
(36, 37). Thus far, this method has been used to explore
the vascular specificity of various peptides after their in-
travenous injection into mice and rats. Peptides capable
of homing to the vasculature of organs and tumor tissues
have been identified in this manner, attesting to the
power of the method (36–38). Peptides targeting selective
markers in the vasculature of specific organs or tissues are
therefore attractive for incorporation into recombinant
viral vectors for targeted gene delivery.
In this study we have explored genetic modification of
the AAV-2 capsid by introducing a peptide motif, NGR,
which targets a receptor, CD13 (39), that is specifically
upregulated in angiogenic vasculature. CD13 is a key reg-
ulator of angiogenesis and functions as a vascular receptor
for the NGR motif in activated blood vessels (39). The
NGR motif has been successfully employed to enhance
the antitumor properties of doxorubicin and tumor ne-
crosis factor (TNF) (38, 40). Based on sequence homolo-
gies and on the results of previous studies, we chose two








































ARTICLEuated the impact of deletions, replacements, and inser-
tions within these loops. We inserted sequences coding
for the motif NGR (38, 39), other organ-homing peptides
(36, 37, 41), or a Myc epitope tag. Recombinant AAV
vectors expressing reporter genes were generated with
modified Cap proteins and analyzed for virus production,
heparin binding, and transduction assays. We show by
immunoprecipitation of epitope-tagged virions that these
loops are presented on the surface of the capsid, although
the degree of accessibility varied. Deletions, modifica-
tions, or insertions within the loops did not affect virus
production. Deletion and large insertions at one of the
loops abolished heparin binding. Transduction of several
cell lines was significantly impaired for most deletions,
mutations, and insertions. However, several mutants con-
taining the NGR peptide displayed an altered tropism
toward cells expressing CD13. These results are discussed
in light of recently reported data, to suggest strategies for
the incorporation of targeting peptides for systemic gene
therapy.
MATERIALS AND METHODS
Plasmids. Plasmid pXX2 (42) was used as a template for the construction of
all modified capsids. Plasmids with deletions of the loop regions (pXX2-
DLoopIII and -DLoopIV) were generated by elongation PCR, introducing
novel MluI and SpeI sites as shown in Fig. 2. The restriction sites were
esigned to allow for the in-frame insertion of oligonucleotides coding for
oreign epitopes. All replacements and insertions were generated from
hese plasmids, except for insertions at the 588 site, which were cloned
sing a novel SpeI site introduced at nucleotide 3967 of AAV2 (GenBank
ccession No. AF043303). All mutated plasmids were sequenced using an
utomated ABI Prism DNA sequencer 377 (PE Biosystems, Foster City, CA).
lasmid pXX6 supplies the adenovirus helper proteins for rAAV produc-
ion (43) and pAAV-GFP contains a recombinant AAV genome with the
reen fluorescent protein flanked by viral inverted terminal repeats and
xpressed from a cytomegalovirus promoter.
Cell culture, transfection, and virus production. All cell lines were main-
ained in Dulbecco’s modified Eagle’s medium supplemented with 10%
etal bovine serum (FBS). Transfections were performed by calcium phos-
hate precipitation according to standard protocols and repeated multiple
imes. To produce rAAV with mutant capsid proteins, we transfected 293T
ells with three plasmids: pXX2, which supplied wild-type or mutant
apsid proteins; pXX6, which contained the adenovirus helper functions;
nd pAAV-GFP. For virus production 5 3 15-cm plates were transfected
each with 6 mg pXX2, 25 mg pXX6, and 19 mg pAAV-GFP and incubated at
37°C for 72 h. Virus was purified using iodixanol gradients as described
elsewhere (44). Wild-type adenovirus type 5 (Ad5) used for titration of
transduction was propagated in 293 cells and purified by sequential
rounds of ultracentrifugation in CsCl gradients. Titers of Ad5 were deter-
mined by plaque assays on 293 cells.
Virus titers, transduction assays, and FACS analysis. The titer of rAAV
genome-containing particles per milliliter was determined by real-time
PCR using SYBR Green I double-stranded DNA binding dye and an ABI
Prism 7700 Sequence Detection System (PE Biosystems). Samples were
prepared as previously described (45). The following primers were chosen
to amplify eGFP: F1, CTGCTGCCCGACAACCA, and R2, CCATGT-
GATCGCGCTTCTC).
To assess transduction, cells grown in 24-well dishes were infected with
rAAV (100–10,000 genomes/cell) and Ad5 (5 plaque forming units/cell) in
fresh medium with 10% FBS. Ad5 co-infection was used to maximize
transduction by rAAV by enhancement of second-strand synthesis as
previously reported (54). Transduction by rAAV-GFP was determined by
counting green cells using an Axiovert25 microscope (Carl Zeiss, Thorn-
wood, NY) equipped with an OSRAM HBO mercury short arc lamp micro-
scope or by FACS analysis using a Becton–Dickinson FACScan (San Jose,966following infection. Cells were photographed using a Nikon (Garden City,
NY) microscope in conjunction with a charge-coupled device camera
(Cooke Sensicam; Cooke Corp., Tonawanda, NY) and images were cap-
tured using SlideBook (Intelligent Imaging Innovation, Denver, CO). All
transduction experiments were repeated at least three times. Expression of
CD13 was measured by FACS using the antibody WM15 (Pharmingen, San
Diego, CA). Each cell type was gated based on the fluorescence obtained
when incubated with mouse IgG antibody. Mouse anti-b1 integrin, clone
P4C10 (Life Technologies, Rockville, MD), was used as a positive control
(100% gated).
Gel electrophoresis, Western blotting, immunoprecipitations, and heparin
binding assays. An equal number of purified rAAV-GFP virions (109 ge-
ome-containing particles) were separated on 8% SDS–polyacrylamide
els and Western blotting was performed to detect capsid proteins. In all
ases proteins were detected by enhanced chemiluminescence (NEN, Bos-
on, MA, and Amersham, Buckinghamshire, UK) according to the manu-
acturer’s instructions. AAV capsid proteins were detected with mAb B1
American Research Products (ARP), Belmont, MA). Immunoprecipitations
ere performed from iodixanol-purified rAAV. Equivalent amounts of
urified virus (1010 genome-containing particles) were precleared with
rotein G–Sepharose (Amersham/Pharmacia, Piscataway, NJ) for 1 h at 4°C
n RIPA buffer (20 mM Tris, pH 8.0, 100 mM NaCl, 0.2% NP-40, 0.2%
riton X-100, and 0.2% deoxycholate). Samples were centrifuged and the
upernatants containing the rAAV particles were incubated at 4°C over-
ight with antibodies A20 (ARP), A69 (ARP), or anti-Myc (Invitrogen,
arlsbad, CA) or a control antibody. Samples were washed four times in
IPA buffer. After being washed, pellets were boiled for 5 min in SDS–
AGE loading buffer. Proteins were separated on 8% SDS–polyacrylamide
els and capsid proteins detected by Western blotting with the B1 anti-
ody.
Viruses with wild-type virions and deletions, insertions, or replacements
1010 genome-containing particles) were bound to 100 ml heparin agarose
(Sigma, St. Louis, MO) in binding/washing buffer (20 mM Tris, pH 7.6, 150
mM NaCl, and 1 mM MgCl2) for 1 h at 4°C. After six washes, bound virus
as eluted with elution buffer (20 mM Tris, pH 7.6, 1 M NaCl). The
ractions were detected by Western blotting using the B1 antibody.
RESULTS
Alignments of Parvovirus Cap Proteins
In order to identify suitable sites for insertion of targeting
peptides, we aligned the amino acid sequences of several
parvoviruses. We performed sequence alignments using
the MacVector software package (Oxford Molecular
Group, UK) and included recently reported sequences for
AAV serotypes 1, 3, 5, and 6 (46–50). Antigenic sequences
of AAV-2 are aligned to the corresponding regions of CPV
in Fig. 1 and are shown as four domains, I, II, III, and IV,
which contain loops 1–4 of CPV (25). We have marked on
these alignments peptides previously identified as anti-
genic sites (see boxes 1–14).
An antigenic region in domain I of CPV (box 3) is the
target of neutralizing antibodies (51, 52). Interestingly, a
nonconserved amino acid sequence of B19, which is also
the target for neutralizing antibodies (box 2) maps to the
same site (53). A peptide containing sequences of AAV-2
which partially overlap with loop 1 of CPV based on
sequence alignments has been shown to inhibit the bind-
ing of neutralizing antibodies to AAV in an ELISA (31). A
minor component of the epitope recognized by the
monoclonal antibody A20 (box 4) also aligns within this
region (30), but this antibody does not inhibit cell bind-
ing. Mutations in either of these two epitopes have beenMOLECULAR THERAPY Vol. 3, No. 6, June 2001
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Cshown to severely impair transduction or destabilize the
AAV capsid (35). A second major antigenic site of CPV lies
within domain II (box 6) (25). An AAV-2 peptide (box 5)
sequence forms an epitope, in conjunction with the pep-
tide A-20 in domain I (box 4), that is recognized by a
monoclonal neutralizing antibody. Taken together, these
results imply that domains I and II are in close proximity
in AAV-2. Moreover, the inability of the antibody that
recognizes this region to inhibit receptor binding suggests
that this region in AAV-2 is not involved in receptor
recognition, but may have an important function in a
later event in the infectious pathway. These putative loop
regions are also well conserved between the different AAV
serotypes (50). Therefore, it seems unlikely that insertion
of targeting peptides at these loops would lead to targeted
AAV transduction.
Several residues in antigenic loop 3 of CPV and the
FIG. 1. Homology alignments of parvovirus Cap proteins. (A) The amino a
2906023; goose parvovirus (GPV), 9628653; B19, GP No. 4092542; minute
494031; and canine parvovirus (CPV), GP No. 494746, were aligned using the
Group, London). The alignments are shown for four domains (I–IV) within the c
blue) and similar sequences (light blue) are highlighted. Antigenic regions wit
details and references). Published mutations and their corresponding sites a
insertions are marked with an arrow (33), filled arrowhead (34), and open arro
(B) Alignments of putative Loops III and IV of the AAV serotypes. The sequence
are shown enclosed by dashed boxes.MOLECULAR THERAPY Vol. 3, No. 6, June 2001
opyright © The American Society of Gene Therapycorresponding residues in related parvoviruses have been
shown to be involved in viral tropism. One of the major
neutralizing epitopes in CPV (box 8) is in the extended
portion of loop 3 on the shoulder of the threefold spike
(51). The AAV-2 sequence that aligns to this region (box
11) is also able to bind neutralizing antibodies; however,
its involvement in receptor attachment is still not clear
(31). All AAVs except serotype 5 contain an insertion at
this site compared to other parvoviruses (Figs. 1A and 1B).
Two monoclonal antibodies against AAV-2 recognize ad-
ditional epitopes within domain III (boxes 9 and 10).
Moreover, two charge-to-alanine mutations in this region
resulted in the production of viruses defective in trans-
duction (35). Rabinowitz et al. found that small insertions
in this region also resulted in decreased transduction (34).
However, insertion of the L14 peptide at residue 447 of
the AAV-2 capsid protein resulted in exposure on the
sequences of the capsid proteins of AAV-2, Genpept Accession No. (GP No.)
of mice (MVM), GP No. 2982110; feline panleukopenia virus (FPV), GP No.
stalW alignment tool of the software program MacVector (Oxford Molecular
id protein, which contain the antigenic loops of CPV. Identical sequences (dark
the loops are enclosed by boxes that are numbered to the right (see text for
dicated and part of the b-barrel is shown with a horizontal arrow. Sites of
ad (35). Numbering of mutations and sites match the corresponding papers.
























ARTICLEsurface of the capsid and increased binding to cells ex-
pressing integrins, but this virus did not retarget transduc-
tion.
Domain IV of AAV-2 contains two sequences which
have been mapped as targets of neutralizing antibodies
(boxes 11 and 14). Mutations in one of these epitopes
resulted in an inability to assemble capsids (35). Muta-
tions and insertions have also shown the involvement of
an adjacent site (box 12) in heparin binding. Although
both regions are variable between AAV serotypes (50), Fig.
1B shows that domain IV is more conserved. Based on the
sequence alignments and previous findings, we decided to
analyze different strategies for the incorporation of organ-
targeting peptides into putative loops within domains III
and IV of AAV-2. We have designated these Loop III and
Loop IV (dotted boxes 7 and 12).
Effects of Deletions within Putative Loops III and IV
of AAV-2
We first asked whether predicted Loops III and IV were
essential for virus assembly and packaging by making dele-
tions within these regions. Mutant plasmids were generated
to encode capsid proteins with deletions of 7 or 6 amino
acids within Loop III and Loop IV, respectively (Fig. 2A).
These constructs were transfected together with a vector
plasmid (pAAV-GFP) and an adenovirus helper plasmid
(pXX6) into 293 cells to generate the mutant viruses rAAV-
GFP-DIII and rAAV-GFP-DIV. Viruses were purified by io-
dixanol gradient ultracentrifugation and the amount of ge-
nome-containing particles was assessed by real-time PCR.
The number of genome-containing particles for the viruses
with the mutated Cap proteins was similar to that of those
generated with wild-type Cap proteins (Fig. 2B). The protein
composition of virions was determined by Western blotting
of proteins from virus preparations having equivalent num-
bers of genome-containing virions. The stoichiometry of the
three Cap proteins was similar to that of wild-type capsids.
The ability of the viruses to transduce target cells was as-
sessed by FACS analysis and fluorescence microscopy. As can
be seen in Fig. 2C, transduction of 293 cells was significantly
impaired for viruses with deletions in Loop III or IV, com-
pared to virus generated with wild-type Cap proteins. These
data suggest that the deleted portions of Loops III and IV are
not essential for assembly or packaging of rAAV virions but
that they have important roles in transduction.
Accessibility of Replacements or Insertions at Loops III
and IV
Having shown that Loops III and IV were nonessential
for assembly and packaging of AAV capsids we next as-
sessed whether heterologous peptides inserted at these
locations were presented on the surface of the virion. We
first replaced the natural sequences of the loops with
oligonucleotides encoding a Myc epitope. In addition to
replacements of deleted sequences, we also selected two
sites within Loops III and IV for insertion of targeting
peptides. One of these sites was at amino acid 449 within968Loop III and the second was at amino acid 588, which is
in predicted Loop IV. The positions of these sites imposed
on the CPV structure crystal structure are shown in Fig.
3A. Loop III is present in an extended conformation pro-
truding from the virus, while Loop IV is in a pocket
conformation, consistent with its putative function as a
receptor anchor. These sites are similar but not identical
to those recently used by others (33, 35).
In order for these sites to be useful in retargeting AAV
vectors, it is necessary for inserted peptides to be presented
on the surface of the virion. To determine the relative ac-
cessibility of peptides at these sites, we assessed the ability of
FIG. 2. Effects of deletions within putative Loops III and IV of AAV-2. (A)
Constructs were generated with deletions in putative Loops III and IV. Sites of
restriction enzymes SpeI and MluI used for cloning oligonucleotides are indi-
ated. Sequences conserved between AAV serotypes are highlighted. Mutation
f a single residue (Q), marked with an asterisk, prevented efficient transduc-
ion (see text for details). Enclosed boxes marked regions deleted. (B) Effect of
eletions on number of genome-containing particles. Recombinant viruses
ith wild-type or mutant capsids were generated by transfections and purified
y iodixanol gradients. Purified genome-containing rAAV vectors were quan-
ified by real-time PCR against plasmid standards and are represented as
enome-containing particles/ml (g.p./ml). (C) Virion composition of purified
apsids. After iodixanol gradient purification an equal quantity of genome-
ontaining virions as determined by real-time PCR (109 genomes) was ana-
yzed by Western blotting with antibody B1. The positions of the capsid
roteins VP1, VP2, and VP3 are indicated. (D) Deletions in Loops III and IV of
AV Cap proteins impair rAAV transduction. Transduction of 293 cells infected
ith rAAV-GFP at an m.o.i. of 1000 genomes/cell in the presence of Ad5
m.o.i. 5 pfu) was assessed after 24–48 h by analyzing GFP expression by FACS
nalysis (left) or fluorescence (right).MOLECULAR THERAPY Vol. 3, No. 6, June 2001





























Can anti-Myc antibody to immunoprecipitate epitope-tagged
capsids (Fig. 3). Constructs for the mutant viruses were
transfected into 293 cells together with the rAAV-GFP vector
plasmid and the adenovirus helper plasmid. Cells were har-
vested and rAAV was purified by iodixanol gradients. The
number of genome-containing particles was assessed by
real-time PCR. Equal numbers of particles (1010 genome-
ontaining particles) were immunoprecipitated using anti-
odies that recognize either intact AAV viral particles (A20)
r the Myc epitope (Fig. 3C). Western blotting with an
nti-Cap antibody (B1) demonstrated that the A20 antibody
ould isolate wild-type and mutant virions with equal effi-
iency. Control wild-type virus was not precipitated with
he Myc antibody. In contrast, the Myc antibody was able to
apture capsids containing the Myc epitope in Loops III and
V. The efficiency of capsid precipitation by the Myc anti-
ody was higher for the insertions (rAAV-449Myc and
AAV-588Myc) compared to the loop replacements (rAAV-
III-Myc or rAAV-DIV-Myc). We confirmed that the differ-
nces between viruses did not reflect immunoprecipitation
f unassembled soluble proteins, by using an antibody to
FIG. 3. Insertions or replacements in Loops III and IV are exposed on the caps
as filled dots on the structure of the CPV Cap protein. (B) A peptide encoding
and 588. Sequences conserved between AAV serotypes are highlighted. (C) T
immunoprecipitation, followed by Western blotting. For each construct rAAV-
Similar numbers of genome-containing particles (1010) were immunoprecip
epitope, or VP2 capsid proteins (A69). Immunoprecipitated proteins were de
indicated.MOLECULAR THERAPY Vol. 3, No. 6, June 2001
opyright © The American Society of Gene TherapyP2 that also recognizes nonassembled Cap proteins (A69).
sing this antibody similar levels of Cap proteins were de-
ected with all viruses. No virus Cap proteins were detected
sing an antibody against a cellular protein as a negative
ontrol (data not shown). These experiments demonstrated
hat in most cases the Myc epitope was accessible to the
ntibody and was therefore presented on the surface of the
ssembled virions. These data confirm the findings of Girod
t al. and Wu et al. (33, 35), who demonstrated surface
xposure of the L14 peptide and HA tag, respectively, when
nserted at adjacent sites. These results also highlight possi-
le differences in the exposure of epitopes when present as
eplacements compared to insertions.
Effects of Replacing or Inserting Targeting Peptides
into Putative Loop III or IV of AAV-2
Having established that sequences could be mutated or
inserted in the putative Loops III and IV, we sought to
assess the effects of incorporating targeting peptides at
these sites. The tripeptide asparagine-glycine-arginine
urface. (A) The positions of antigenic Loops III (green) and IV (blue) are shown
Myc epitope tag either replaced Loops III or IV or was inserted at residues 449
ccessibility of the Myc epitope in the fully assembled capsid was assessed by
was generated by transfection and particles purified by iodixanol gradients.
d using antibodies that recognize intact AAV viral particles (A20), the Myc











































ARTICLE(NGR) was isolated using the in vivo phage selection sys-
em in which peptides capable of homing to tumor an-
iogenic vasculature were recovered from phage libraries.
eptides containing an NGR motif bind selectively to
D13 in vivo in tumor- and hypoxia-activated blood ves-
els (39). Oligonucleotides encoding this sequence were
loned into the putative loops, either as replacements of
he original sequence or as insertions. Recombinant vi-
uses for the replacements (rAAV-DIII-NGR or rAAV-DIV-
GR) or insertions (rAAV-449NGR and rAAV-588NGR)
ere generated by transfections and purified by iodixanol
radients. Control viruses contained the Myc epitope as a
eplacement (rAAV-DIII-Myc or rAAV-DIV-Myc) or inser-
ion (rAAV-449Myc and rAAV-588Myc) at the same sites.
he numbers of genome-containing particles were deter-
ined by real-time PCR and in all cases they were com-
arable to those obtained with wild-type capsid proteins
Fig. 4). The stoichiometry of these purified capsids was
etermined by Western blotting with a Cap antibody and
emained the same with all modified capsids.
FIG. 4. Effects of replacements or insertions within the putative loops. Effects
were quantified by real-time PCR against plasmid standards and are represe
wild-type and mutant viruses after iodixanol purification was assessed by Weste
PCR (109 genomes) were subjected to SDS–PAGE and Cap proteins detected b
of Loops III and IV of the AAV Cap impair rAAV transduction (right). Transduc
Ad5 (m.o.i. 5 pfu/cell) for 24–48 h was quantified by FACS analysis. Presente970First, we tested the ability of the engineered viruses
ontaining replacements or insertions to transduce 293T
ells. Cells were transduced with 1000 genome-contain-
ng particles of rAAV per cell in the presence of adenovirus
o-infection to maximize transduction (54). Despite their
bility to assemble and package AAV particles, these mu-
ant viruses were significantly impaired for transduction
n 293T cells, with efficiencies ranging from 0.5 to 15% of
ild-type (Fig. 4). Transduction was most severely im-
aired for viruses that contained the Myc epitope in Loop
V, either as a replacement or as an additional insertion. A
itration of infections over a range of m.o.i. revealed that
egardless of the amount of particles used, rAAV-DIV-Myc
nd rAAV-588Myc were unable to achieve more than
.5% the transduction efficiency of wild-type virions
data not shown). These results confirm that targeting
eptides can be inserted into the putative loops without
ffecting assembly and packaging but transduction is im-
aired.
oop replacements (A) or peptide insertions (B) on vector titers. Purified viruses
d as genome-containing particles/ml (g.p./ml) (left). Virion composition of
lotting (center). Equal quantities of purified virions as determined by real-time
estern blotting with antibody B1. Replacements and insertions within regions
of 293 cells infected with rAAV-GFP at an m.o.i. of 1000 in the presence of





d aMOLECULAR THERAPY Vol. 3, No. 6, June 2001
Copyright © The American Society of Gene Therapy
ARTICLE
CHeparin Binding of AAV Capsids Containing
Heterologous Peptide Sequences
One possible cause for the reduced infectivity of rAAV
mutants containing foreign epitopes could be their inabil-
ity to bind the viral cell surface receptors. A primary
receptor for AAV-2 has been reported to be heparan sul-
fate proteoglycan (12). To test whether viruses with mu-
tant capsids could bind heparin, we performed heparin
batch binding experiments and detected the viruses by
Western blotting using the B1 antibody (Fig. 5). Recom-
binant viruses purified by iodixanol gradient centrifuga-
tion were bound to heparin agarose for 1 h at 4°C. Fol-
lowing incubation of the viruses with heparin agarose,
the unbound fraction was removed. After extensive wash-
ing of the heparin agarose, viruses were eluted in 1 M
NaCl. As expected, viruses containing a wild-type capsid
had a high affinity for the heparin agarose, and negligible
amounts of virus were found in the unbound fraction.
About 20% of the input virus was recovered in the elution
from the beads. Most mutants had a binding and elution
profile similar to that of the wild-type capsids. However, a
deletion of 6 amino acids (GNRQAA) from Loop IV abol-
ished binding to heparin. Interestingly, replacement of
this sequence with the NGRAHA peptide sequence re-
stored the ability of the mutant capsid to bind heparin
FIG. 5. Analysis of WT and mutant capsid virus binding to heparin. Iodixanol
extensive washing, bound virus was eluted with 1 M NaCl. The fractions were
the B1 antibody. Shown are 5% of input virus (I), 5% of the unbound fraction
indicated.MOLECULAR THERAPY Vol. 3, No. 6, June 2001
opyright © The American Society of Gene Therapy(Fig. 5). Viruses with the Myc epitope tag in the Loop IV
region were unable to bind heparin, which suggests that
this region is important for attachment to the primary
receptor. This is also consistent with their poor transduc-
tion efficiency (Fig. 4).
Altered Tropism of rAAV Containing the Tumor-
Targeting Peptides
To determine whether incorporation of targeting pep-
tides could alter the tropism of rAAV we tested transduc-
tion on a number of cell lines (Fig. 6). For this purpose we
employed two highly tumorigenic cell lines. Kaposi sar-
coma (KS1767) cells are derived from Kaposi sarcoma
lesions (38). The second cell line tested was an embryonal
rhabdomyosarcoma cell line (RD). Both cell lines express
high levels of CD13, the NGR receptor, as assessed by
FACS analysis (RD and KS1767 were 57 and 99% positive
for CD13 compared to 8 or 3% positive for 293T and HeLa
cells). Viruses were first titered on 293 cells and then equal
transduction units of the different viruses were used to
infect the other cells. An amount was chosen that resulted
in 10% transduction of 293 cells as assessed by FACS
analysis for GFP expression. Using these adjusted values,
similar transduction efficiencies were seen for the viruses
on HeLa cells (Figs. 6A and 6B). However, rAAV consisting
dient-purified rAAV viruses were bound to heparin agarose for 1 h at 4°C. After
arated on SDS–8% acrylamide gels and analyzed by Western blotting using





ARTICLEof wild-type capsids transduced the KS1767 and RD cell
lines very poorly. In contrast, viruses containing the
NGRAHA sequence at Loop IV, either as a replacement or
as an insertion, were able to transduce these cell lines 10-
to 20-fold better than wild type (Fig. 6A). This altered
tropism was not observed for viruses with deletion of
Loop IV or the Myc epitope at this site.
In the context of the phage coat protein or as a syn-
thetic peptide, targeting was most efficient with cyclic
peptides containing four cysteine residues (38). Based on
the data from phage display libraries we included se-
quences containing the targeting NGR motif in the po-
tentially cyclic (two cysteines) or double cyclic forms.
Viruses containing the cyclic NGR sequences were
less efficient than those with the linear peptide in trans-
duction of 293 and HeLa cells but they also displayed
enhanced tropism toward the tumorigenic, CD-13-posi-
tive cell lines RD and KS1767 (Table 1 and data not
shown).
FIG. 6. Altered tropism of rAAV containing the NGRAHA sequence. Viruses we
n equal amount of transduction units (able to achieve 10% transduction of
o 1 3 107, 2 3 108, 5 3 108, and 4 3 108 genome-containing particles for W
h postinfection, by counting green cells under a fluorescence microscope or b
capsid in the different cell lines. (B) Images of GFP expression captured by fluo
viruses but those containing NGR peptides showed preferential transduction o
FACS analysis with the WM15 antibody) and altered tropism of NGR-contain972Several sequences have been isolated from phage dis-
play libraries and shown to home to different tissues in
vivo. These include lung-, brain-, tumor-, and muscle-
homing peptides (36, 55–57). We inserted a number of
these targeting peptides into the 588 site, which we had
defined as appropriate for accepting heterologous se-
quences (see Table 1). These included a GFE-containing
peptide to target membrane dipeptidase expressed on
lung vasculature (55), a muscle-homing peptide (56), and
sequences identified in an in vitro phage display screen for
NG2 proteoglycan binding sequences (57). Some of the
viruses containing other targeting peptides were pro-
duced less efficiently and we were not able to observe
altered tropism in the appropriate cell lines (Table 1). In
general, we observed that smaller peptides were tolerated
better than larger ones. Even at the same site we saw an
effect of the sequence that was inserted, with linear pep-
tides having fewer deleterious effects than sequences con-
taining multiple cysteine residues.
nitially titered for transduction on 293 cells by FACS analysis of GFP expression.
cells) was used to infect 293, HeLa, KS1767, and RD cells. These correspond
IV, DIV-NGR, and 588NGR, respectively. Transduction was assessed at 24–72
CS analysis. (A) Transduction efficiencies are shown relative to the wild-type
ence microscopy. Transduction of HeLa cells was comparable for the different
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Homing peptides isolated by in vivo screening of phage
display libraries provide novel tools for selective vascular
targeting of therapies and are attractive for incorporation
into viral vectors (36–38, 41, 58). It is unclear whether
these peptides will be presented in the correct conforma-
tion on viral particles to enable targeting of modified
vectors. We recently used targeting peptides to redirect
adenoviral vectors to specific endothelial receptors using
bispecific conjugates with antibodies recognizing adeno-
virus particles (59). Tumor-targeting peptides have also
been successfully used to enhance the antitumor proper-
ties of doxorubicin and TNF (38, 40). In this study, we
were able to generate modified AAV-2 capsids that con-
tain targeting peptides, previously isolated by in vivo
phage display. Peptides were incorporated as either re-
placements of native sequences or insertions. Modifica-
tion of putative loops did not affect replication, assembly,
and packaging of rAAV vectors. We show that the precise
site of insertion and the choice of replacement of the
original sequence can have an impact on the accessibility
of the peptide at the capsid surface. We found that the
transduction efficiency of rAAV-2 vectors bearing such
peptides was severely compromised, but that in some
cases we could demonstrate altered preference for trans-
duction of tumor cells. This study represents the first
attempt to target rAAV by genetic incorporation of tumor-
targeting peptides previously isolated by phage display
technologies. We were able to generate AAV viruses con-
taining linear, cyclic, and double-cyclic versions of the
NGR and these vectors showed altered tropism, with pref-
erential transduction of cells that express the CD13 recep-
tor.
Alignments of available sequences for all the parvovirus
capsid proteins highlight large areas of sequence conser-
Properties of Recombinant AAV Viruses Conta
Virusa Homing peptideb Titerc (g.p./m
588 GFE-4C CGFECVRQCPERC 2.50 3 109
88 NGR-2C CNGRC 6.00 3 1010
588 NGR-4C CNGRCVSGCAGRC 4.30 3 109
588 L14 QAGTFALRGDNPQ 1.50 3 1010
588 MH ASSLNIA 7.70 3 1010
588 NG2-1 TAASGVRSMH 1.00 3 1011
88 NG2-2 LTLRWVGLMS 6.60 3 109
a Homing peptides were introduced into the AAV capsid at amino
pXX6 as a helper to package a GFP expression cassette.
b See text for details.
c Viruses were purified by iodixanol gradient centrifugation and
particles (g.p./ml).
d Transduction was assessed in 293 cells by FACS analysis and is p
e Cell lines used to assess targeting of an equal amount of transdu
f Altered tropism was tested in the indicated cell lines. ND, not d
g MDA-MB-435-MBP (59).MOLECULAR THERAPY Vol. 3, No. 6, June 2001
opyright © The American Society of Gene Therapyvation (29). Sequences that make up the b-barrel are the
most conserved. Consistent with this are genetic studies
in which mutations within these regions result in nonin-
fectious viruses, many of which do not make intact cap-
sids (34, 35, and M.G. and M.D.W., unpublished data). A
comparison of our alignment to the previously published
ones (29, 33) reveals some differences, especially in vari-
able regions where sequence similarity is low and inser-
tions are present. We have also extended the alignments
presented in Fig. 1 by including additional parvoviral
sequences (e.g., Kilhamrat, porcine, and simian), which
enhance the confidence of the alignment we show (data
not shown). When the three-dimensional structure of the
AAV-2 capsid is solved, the validity of these hypothetical
alignments will be assessed by superimposing the actual
structures. We were able to make deletions within the
putative Loops III and IV of AAV-2 without causing any
detrimental effects on virus assembly or packaging. This is
in contrast to previous studies with CPV, in which dele-
tions in loops 1, 3, and 4 affected capsid assembly and
morphology (60). It should be noted, however, that in the
CPV study the deletions were larger (12–16 amino acids)
and the assay for assembly was the formation of virus-like
particles after infection of insect cells with recombinant
baculoviruses expressing the Cap proteins. Despite our
ability to modify these loop regions we encountered some
residues that were far more sensitive to alterations. For
example a single point mutation within Loop IV (Q584S)
completely abrogated rAAV transduction (data not
shown). The dramatic effect of deletions in Loops III or IV
on transduction by rAAV vectors suggests that these two
regions are indeed involved in the infectious pathway.
This may be at the level of attachment to cellular recep-
tors or some additional step during internalization, cyto-
plasmic trafficking, or nuclear entry of the virus particle.
g Homing Peptides in Their Capsid Proteins
Transductiond








id 588 and recombinant viruses were produced in 293T cells using
red by real-time PCR. Titers are presented in genome-containing
ented as a percentage of WT.













































































ARTICLEThree cellular receptors have been implicated in AAV
infection (HSPG, FGFR-1, and aVb5 integrin) although
irect involvement of these proteins has recently been
alled into question (61–63). We could confirm that pu-
ative Loop IV is required for binding to heparin, which is
onsistent with its attachment to the proposed HSPG
rimary receptor (12) and recent mapping of two heparin-
inding clusters (34, 35). We have not yet investigated
inding of these mutants to the putative secondary recep-
ors. It is interesting to note that while deleting a part of
oop IV abolishes heparin binding, replacing it with the
GR targeting peptide could restore binding. Replace-
ent of the same sequence in Loop IV with the Myc
pitope was unable to rescue heparin binding. The NGR
eptide is similar to the sequence that has been deleted,
uggesting that replacement of capsid epitopes with resi-
ues resembling the original sequence in size and charge
ay be well tolerated.
In order for rAAV vectors with altered tropism to be
iable for clinical applications it is important that the
roduction, packaging, and transduction efficiencies of
he modified viruses are not severely compromised. One
revious attempt to target AAV capsids required transfec-
ion of the modified capsid construct together with wild-
ype virus and gave a very low yield of virus (32). We
ound that our modified viruses were similar to wild type
n their ability to replicate and package a vector genome
ut in almost every case the transduction of the modified
apsid was suboptimal. This has been a common problem
or all attempts so far to retarget rAAV vectors (33, 35).
ur data suggest that this is due to a combination of size,
equence, and insertion site. We have found that larger
eptides tend to have more detrimental effects on the
roperties of the modified virus particle. While some pep-
ides such as the NGR and L14 (33) have been tolerated
or insertion in Loops III and IV, others such as the serpin
igand resulted in no capsid formation (35). We have been
ble to show altered tropism for vectors containing tar-
eting peptides but in all cases this was at the expense of
ransduction efficiency, which would not be acceptable
or clinical applications.
Successful retargeting of rAAV vectors is likely to come
rom a delicate combination of the type of peptide in-
erted and the choice of insertion site. A number of stud-
es have now described multiple sites that can be used for
eptide insertions (32–35). In this study we have focussed
n a limited number of sites and inserted multiple differ-
nt sequences in two approaches, replacements or inser-
ions. Our data suggest that the best approach may be to
can the AAV sequence for putative surface-exposed areas
hat contain nonconserved protein sequences matching
he sequence to be inserted and replace these regions with
he targeting ligand. Perhaps this may be best achieved
hrough a combinatorial library approach, whereby rAAV
ectors with modified capsids are selected directly for a
iven target. Libraries could also be used to select for
iruses that have inserted peptides but also maintain
ransduction levels similar to those of wild-type capsids.
ne potential problem with a small virus such as AAV is974he transduction process may be structurally linked, such
s in CPV (64). Further studies of the pathways of AAV
nfection and rAAV transduction will reveal the role of
ifferent parts of the capsid in the infection entry process.
he ability to restrict AAV-2 gene delivery to a specific
rgan or tissue will allow the use of smaller dosages of
irus and will be important in limiting toxicity following
ystemic in vivo administration in a wide range of gene
herapy applications.
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